The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Condition: Non-squamous Non-small-cell Lung Cancer Interventions: Drug: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed; Drug: Sintilimab+Carboplatin or Cisplatin+Pemetrexed; Drug: Tusamitamab ravtansine+Sintilimab Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2023 Category: Research Source Type: clinical trials
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Condition: Non Squamous Non Small Cell Lung Cancer Intervention: Drug: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin Sponsor: CrystalGenomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2023 Category: Research Source Type: clinical trials
